Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
NCT ID: NCT00143520
Last Updated: 2021-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
441 participants
INTERVENTIONAL
2004-12-31
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Rivoglitazone in Type 2 Diabetes Mellitus
NCT00484198
Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes
NCT00575874
Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes
NCT00575471
Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus
NCT00571519
Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone
NCT00641043
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rivoglitazone
Pioglitazone
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between 18 and 75 years of age
* With a HbA1c greater than or equal to 7.5% and less than 10.5% at randomization
Exclusion Criteria
* Patients unwilling or unable to discontinue their anti-diabetic medication(s)
* History of ketoacidosis
* History of therapy with rosiglitazone, troglitazone, pioglitazone
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daiichi Sankyo
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daiichi Sankyo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Columbiana, Alabama, United States
Huntsville, Alabama, United States
Muscle Shoals, Alabama, United States
Hot Springs, Arkansas, United States
Jonesboro, Arkansas, United States
Little Rock, Arkansas, United States
Searcy, Arkansas, United States
Sherwood, Arkansas, United States
Los Angeles, California, United States
Moreno Valley, California, United States
Sacramento, California, United States
San Diego, California, United States
San Mateo, California, United States
Santa Monica, California, United States
Torrance, California, United States
Vista, California, United States
West Hills, California, United States
Newark, Delaware, United States
Clearwater, Florida, United States
Cocoa Beach, Florida, United States
Jupiter, Florida, United States
Largo, Florida, United States
Miami, Florida, United States
New Port Richey, Florida, United States
Palm Harbor, Florida, United States
Pembroke Pines, Florida, United States
Tampa, Florida, United States
West Palm Beach, Florida, United States
Warner Robins, Georgia, United States
Chicago, Illinois, United States
Gurnee, Illinois, United States
Evansville, Indiana, United States
Lexington, Kentucky, United States
New Orleans, Louisiana, United States
Detroit, Michigan, United States
Livonia, Michigan, United States
Kansas City, Missouri, United States
St Louis, Missouri, United States
Bozeman, Montana, United States
Butte, Montana, United States
Great Falls, Montana, United States
Voorhees Township, New Jersey, United States
Rochester, New York, United States
Charlotte, North Carolina, United States
Statesville, North Carolina, United States
Winston-Salem, North Carolina, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Marion, Ohio, United States
Clinton, Oklahoma, United States
Oklahoma City, Oklahoma, United States
Tulsa, Oklahoma, United States
Medford, Oregon, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Charleston, South Carolina, United States
Simpsonville, South Carolina, United States
Bristol, Tennessee, United States
Carrollton, Texas, United States
Conroe, Texas, United States
Houston, Texas, United States
Midland, Texas, United States
San Antonio, Texas, United States
Spring, Texas, United States
Sugar Land, Texas, United States
Norfolk, Virginia, United States
Richmond, Virginia, United States
Virginia Beach, Virginia, United States
Lakewood, Washington, United States
Olympia, Washington, United States
Renton, Washington, United States
Spokane, Washington, United States
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Truitt KE, Goldberg RB, Rosenstock J, Chou HS, Merante D, Triscari J, Wang AC. A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes. Curr Med Res Opin. 2010 Jun;26(6):1321-31. doi: 10.1185/03007991003715079.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CS0011-203
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.